The federal government is rebranding Canada’s troubled vaccine injury compensation system, replacing the Vaccine Injury Support Program (VISP) with a new name: the Vaccine Impact Assistance Program. The change comes after years of criticism, delays, and controversy surrounding how the program has handled claims from Canadians who say they were seriously injured by COVID-19 vaccines.
The softer language is difficult to ignore.
“Impact assistance” sounds like a minor inconvenience — the sort of bureaucratic phrasing used to soften uncomfortable realities. Gone is the direct reference to “injury,” replaced with terminology that feels less urgent, less severe, and far less politically charged. For critics, the shift raises concerns that the government is attempting to manage optics rather than address the deeper structural failures that have plagued the program since its creation.
A program under scrutiny
The Vaccine Injury Support Program was originally introduced as a safety net for Canadians who experienced serious and permanent side effects from Health Canada-authorized vaccines. It was marketed as a fair and timely system that would provide financial support and assistance to those affected, ensuring that no one would be left behind if rare adverse reactions occurred.
In theory, it was a necessary component of public health policy. Most developed countries maintain some form of vaccine injury compensation program, recognizing that while vaccines provide widespread societal benefits, a small number of individuals may experience serious adverse effects and deserve support.
In practice, however, the Canadian system quickly became mired in controversy.
Critics have pointed to long delays, complicated application processes, high denial rates, and limited transparency as signs that the system was not built to handle the volume of claims it received. Applicants have reported waiting more than a year for responses, struggling to navigate paperwork requirements, and facing uncertainty about whether their claims would ever be resolved.
These concerns were compounded by questions about how program funding was being spent.
Consultants and cost concerns
Administration of the program was contracted to a private consulting firm, Oxaro (formerly Raymond Chabot Grant Thornton Consulting), which was tasked with managing claims and distributing compensation. Over time, reports surfaced that tens of millions of taxpayer dollars had been directed toward administrative and consulting costs, raising concerns about whether too much funding was being absorbed by bureaucracy rather than reaching injured Canadians.
The optics were troubling.
While consultants were being paid to manage the system, applicants continued to report delays and limited communication. For many observers, this created the perception that the program was structured in a way that prioritized administration over outcomes, leaving those it was meant to help stuck in a slow-moving process with little accountability.
This growing criticism ultimately led to the federal government stepping in, with the Public Health Agency of Canada taking over direct management of the program and introducing the new Vaccine Impact Assistance Program.
A new name, but the same questions
The transition raises a fundamental question: does a new name and new management structure actually fix the underlying problems?
During the transition period, services are expected to be limited, with online systems temporarily unavailable and processing timelines uncertain. For individuals already waiting months or years for decisions, this creates additional concern that delays could continue or even worsen.
Rebranding alone does not address the key issues that critics have identified — transparency, efficiency, accountability, and timely support for those who qualify for assistance.
Without clear reporting on how many claims are approved, denied, or pending, it becomes difficult for the public to assess whether the system is working as intended. Without firm timelines, applicants remain in limbo. Without independent oversight, the government effectively becomes both administrator and evaluator of its own program.
Trust and accountability
At its core, the controversy surrounding the vaccine injury program is about trust.
Public health systems rely heavily on public confidence. When governments promote vaccination campaigns, they often emphasize safety and effectiveness, while also acknowledging that rare adverse effects can occur. Compensation programs are meant to reinforce that trust by demonstrating that individuals who suffer serious side effects will be supported.
If that support appears slow, opaque, or insufficient, confidence in the system can erode.
The shift from VISP to the Vaccine Impact Assistance Program may be intended to signal a fresh start, but trust is not rebuilt through branding alone. It is rebuilt through clear communication, transparent data, faster claim processing, and meaningful support for those affected.
The path forward
If the federal government hopes to restore confidence in the program, several steps would likely need to follow the rebranding.
Regular public reporting on claims and outcomes would improve transparency. Clear timelines for processing applications would reduce uncertainty. Independent oversight could ensure accountability. Most importantly, the program would need to demonstrate that financial support is reaching those who qualify in a timely and consistent manner.
Without these changes, the rebranding risks being seen as little more than a cosmetic fix — a new label applied to an old and troubled system.
For Canadians who believe they were seriously injured and are still waiting for answers, the name of the program matters far less than whether it actually delivers on its promise.
A new acronym may change the optics, but only real reform will change the reality.
